Developer docs
API playgroundTry for free, no card

Search company profiles

PHARMAJET

Full company profile

uuid00008me

Namestring
PHARMAJET
Legal namestring
PharmaJet, Inc.
Websiteurl
pharmajet.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

PharmaJet is a commercial-stage medical device company founded in 2005 and headquartered in Golden, Colorado, that develops spring-powered needle-free jet injection systems for vaccines and injectable therapeutics. Its two commercial product lines, Tropis (0.1 mL intradermal) and Stratis (0.5 mL intramuscular/subcutaneous), deliver a fixed-dose fluid jet in approximately 1/10 of a second without needles, sharps, or external power. Both systems have achieved WHO PQS prequalification, CE Mark, and (for Stratis) FDA 510(k) clearance, enabling procurement by UN agencies and global immunization programs.

The company's business model combines direct hardware sales of reusable devices and disposable sterile syringes with technology licensing and co-development agreements with pharmaceutical and biotechnology partners. It has supplied more than 20 million needle-free injections globally across polio eradication campaigns in Pakistan, Nigeria, Afghanistan, Somalia, and Egypt, and supports 50+ active studies and 80+ completed studies with named partners including Scancell, Nykode, Gennova, Zydus, and Immuno Cure across oncology, infectious disease, and DNA/mRNA vaccine platforms.

PharmaJet operates a hybrid B2B MedTech go-to-market combining direct enterprise sales to pharmaceutical/biotech companies, channel distribution (notably with EVA Pharma/ATR in the Middle East and Africa), and institutional partnerships with global health organizations (WHO, Gates Foundation, PATH, CDC, AFENET, USAID). The company maintains regulatory, clinical, and commercial infrastructure spanning 11–50 employees and is currently expanding into self-injection pens for home use in chronic disease management, funded in part by a 2023 strategic investment from Japan's Daicel Corporation.

Short descriptiontext

PharmaJet is a Golden, Colorado-based commercial-stage MedTech company that develops WHO-prequalified, FDA-cleared, and CE-marked spring-powered needle-free jet injection systems (Tropis, Stratis) for vaccines and therapeutics, serving pharmaceutical/biotech partners and global immunization programs across 20+ million administered doses.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGolden, United States
HQ citystring
Golden
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
needle-free injection, intradermal delivery systems, vaccine delivery devices, jet injection technology, medical device manufacturing
Industry2 codes
PRIMARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Needle-free injection medical devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Hardware Sales
TypeHardware Sales
Description

PharmaJet generates revenue through the sale of its needle-free injection systems (Tropis and Stratis devices) and associated sterile, auto-disabling syringes. The company sells directly to healthcare providers, pharmaceutical partners, and through distribution agreements with regional partners. Pricing is comparable to traditional needle injections with reduced dose volume enabling cost savings for intradermal delivery.

pharmajet.com
2Technology Licensing and Partnership Agreements
TypeLicensing Royalties
Description

Revenue generated through strategic partnerships with pharmaceutical and biotechnology companies where PharmaJet's technology is used for partner product delivery. This includes co-development agreements, technology transfer arrangements, and potentially milestone payments tied to clinical and commercialization progress.

pharmajet.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Comparable to needle and syringe pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

The cost of an injection with PharmaJet Precision Delivery Systems is comparable to a needle injection. Reduced dose volume enabled by Tropis intradermal delivery can decrease vaccine delivery costs by 50%.

pharmajet.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Tropis
Description

Needle-free Injection System for 0.1 mL intradermal injections. WHO prequalified, CE marked device for precise intradermal delivery.

pharmajet.com
+2 more records
Core offering1 text field

PharmaJet develops and manufactures spring-powered needle-free jet injection systems for delivering vaccines and therapeutics without needles. Its two commercial systems are the Tropis ID device for 0.1 mL intradermal injections and the Stratis IM/SC device for 0.5 mL intramuscular and subcutaneous injections, both cleared by FDA, CE Marked, and WHO PQS prequalified, with reusable auto-disabling syringe components sold alongside the devices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 87% of recipients report no pain with Tropis; 69% reduced soreness compared to needles
+8 more records
Product overview1 text field

PharmaJet offers a portfolio of commercial-stage needle-free injection systems consisting of two core products: the Tropis® ID system for 0.1 mL intradermal delivery and the Stratis® IM/SC system for 0.5 mL intramuscular and subcutaneous injections. Both systems are spring-powered devices that deliver medications through a narrow high-velocity fluid jet in approximately 0.1 seconds without needles. The company is also developing needle-free self-injection pens for home use targeting chronic disease management. All products share the core needle-free delivery technology platform, with variations in dose volume and injection depth to serve different therapeutic applications.

Product and service3 records
1Tropis ID Needle-free Injection System
CategoryNeedle-free injection device
Description

A spring-powered needle-free injection system that delivers a precise 0.1 mL intradermal dose in approximately 1/10 of a second, designed for intradermal vaccine and therapeutic delivery. WHO prequalified and CE Mark certified, used in polio immunization campaigns and clinical vaccine delivery globally.

2Stratis IM/SC Needle-free Injection System
CategoryNeedle-free injection device
Description

A spring-powered needle-free injection system for 0.5 mL intramuscular and subcutaneous injections, used to deliver medications and vaccines. Has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification.

3Needle-free Self-Injection Pens
CategoryNeedle-free self-injection device
Description

Proprietary reusable needle-free self-injector pens being developed for home use, designed to improve patient compliance and address needle aversion, particularly for chronic disease management and metabolic peptide therapies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-07
Description

Partnership with AFENET to deploy Tropis ID needle-free injection system for delivering approximately 1.4 million doses of fractional inactivated polio vaccine (fIPV) during polio immunization campaigns in Nigeria. AFENET collaborates with ministries of health to implement polio eradication initiatives.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Clinical study agreement to evaluate Tropis ID needle-free injection device as delivery system for tuberculin skin test. Study will assess accuracy, workflow efficiency, safety, and acceptability compared to traditional needle and syringe administration.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-30
Description

Distribution agreement signed at CPHI meeting in Frankfurt for Tropis needle-free injection systems covering Egypt and Middle East and Africa region. Collaboration aims to improve immunization coverage, reduce costs, and increase vaccine acceptance through Tropis distribution, technology transfer, and local manufacturing.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2025-06-19
Description

Agreement for clinical development of HIV therapeutic DNA vaccine (ICVAX) delivered via PharmaJet Tropis needle-free injection system. Aims to evaluate safety and immunogenicity in human clinical study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-09
Description

Partnership for development and commercialization of SCIB1/iSCIB1+ DNA immunotherapy for advanced melanoma using PharmaJet Stratis needle-free delivery. Phase 2 clinical data showed positive results; advancing to late-stage clinical development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

PharmaJet delivery systems used in multiple Nykode clinical trials for cancer vaccines targeting cervical cancer, head and neck cancers, and metastatic solid tumors. Positive interim Phase 2 results announced for HPV+ cervical cancer trial.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

GEMCOVAC-OM self-amplifying mRNA COVID-19 booster vaccine exclusively delivered with Tropis needle-free system. Received emergency use authorization in India - world's first room temperature stable mRNA vaccine.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

ZyCoV-D plasmid DNA COVID-19 vaccine exclusively delivered with Tropis. World's first plasmid DNA COVID-19 vaccine for administration in humans, receiving emergency use authorization in India.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

WHO supported development of Tropis system and awarded WHO PQS prequalification. Tropis selected for WHO polio eradication campaigns in Pakistan, Nigeria, Afghanistan, and Somalia.

10PATH
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International health organization co-supported development of Tropis needle-free system. Partner on Nigeria implementation study for routine immunization using Tropis-delivered fIPV.

pharmajet.com
11CDC
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

U.S. Centers for Disease Control supported development of Tropis system. House-to-house campaign administration study published in MMWR.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Portal Instruments is developing a high-velocity jet injection platform for needle-free drug delivery, including biologic and large-volume applications. It is the most direct competitor to PharmaJet in needle-free jet injection technology, targeting pharmaceutical partners for drug-device combination products.

2INJEX Pharma
TypeDirect peer
Description

INJEX Pharma offers a spring-powered needle-free jet injection system for insulin and other injectable therapies, marketed primarily in Europe and select international markets. It directly competes with PharmaJet's Tropis and Stratis devices in the needle-free injection device category.

TypeDirect peer
Description

Crossject develops needle-free jet injection systems (Zeneo platform) for emergency and routine drug delivery, including vaccines and biologics. It competes with PharmaJet in the needle-free injection device category and has pursued similar partnerships with pharmaceutical companies and global health organizations.

TypeDirect peer
Description

Antares Pharma, acquired by Halozyme, developed auto-injector and needle-free jet injection platforms for self-administered pharmaceuticals. It is a direct peer in the drug delivery device space serving pharmaceutical partners, though with a stronger focus on auto-injectors than pure jet injection.

TypeDirect peer
Description

Bioject was a pioneer in needle-free jet injection technology, developing the Biojector 2000 and partnering with pharmaceutical companies for vaccine and therapeutic delivery. It is a historical direct competitor to PharmaJet in the jet injection space, though its commercial footprint has been limited.

TypeBroad incumbent
Description

BD is the dominant global manufacturer of conventional needle-and-syringe injection systems, prefilled syringes, and auto-injectors used across pharmaceutical and immunization applications. It is a broad incumbent that competes with PharmaJet in the underlying drug delivery device market, including immunization programs.

TypeBroad incumbent
Description

West Pharmaceutical Services is a leading provider of drug delivery device components and containment systems, including prefilled syringe and auto-injector platforms for pharmaceutical partners. It serves overlapping pharmaceutical customers as PharmaJet and is a broad incumbent in injectable drug delivery.

TypeBroad incumbent
Description

Stevanato Group provides drug containment, delivery devices, and integrated solutions for pharmaceutical and biotechnology partners, including self-injection platforms. It competes with PharmaJet's emerging self-injection pen initiative and serves similar pharmaceutical customers across biologics and vaccines.

TypeBroad incumbent
Description

Ypsomed is a leading developer and manufacturer of self-injection pen platforms and auto-injectors for pharmaceutical and biotech partners, particularly in diabetes, obesity (GLP-1), and biologics. It is a direct competitor to PharmaJet's self-injection pen initiative for chronic disease and metabolic peptide markets.

TypeEmerging player
Description

Inovio develops DNA vaccines and CELLECTRA electroporation delivery technology for cancer and infectious disease applications. It competes with PharmaJet in the delivery technology for next-generation DNA/mRNA vaccines, though using electroporation rather than jet injection, and serves overlapping pharmaceutical and academic research customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PHARMAJET

Needle-free injection medical devicespharmajet.com

PharmaJet is a Golden, Colorado-based commercial-stage MedTech company that develops WHO-prequalified, FDA-cleared, and CE-marked spring-powered needle-free jet injection systems (Tropis, Stratis) for vaccines and therapeutics, serving pharmaceutical/biotech partners and global immunization programs across 20+ million administered doses.

What PHARMAJET does

PharmaJet is a commercial-stage medical device company founded in 2005 and headquartered in Golden, Colorado, that develops spring-powered needle-free jet injection systems for vaccines and injectable therapeutics. Its two commercial product lines, Tropis (0.1 mL intradermal) and Stratis (0.5 mL intramuscular/subcutaneous), deliver a fixed-dose fluid jet in approximately 1/10 of a second without needles, sharps, or external power. Both systems have achieved WHO PQS prequalification, CE Mark, and (for Stratis) FDA 510(k) clearance, enabling procurement by UN agencies and global immunization programs.

The company's business model combines direct hardware sales of reusable devices and disposable sterile syringes with technology licensing and co-development agreements with pharmaceutical and biotechnology partners. It has supplied more than 20 million needle-free injections globally across polio eradication campaigns in Pakistan, Nigeria, Afghanistan, Somalia, and Egypt, and supports 50+ active studies and 80+ completed studies with named partners including Scancell, Nykode, Gennova, Zydus, and Immuno Cure across oncology, infectious disease, and DNA/mRNA vaccine platforms.

PharmaJet operates a hybrid B2B MedTech go-to-market combining direct enterprise sales to pharmaceutical/biotech companies, channel distribution (notably with EVA Pharma/ATR in the Middle East and Africa), and institutional partnerships with global health organizations (WHO, Gates Foundation, PATH, CDC, AFENET, USAID). The company maintains regulatory, clinical, and commercial infrastructure spanning 11–50 employees and is currently expanding into self-injection pens for home use in chronic disease management, funded in part by a 2023 strategic investment from Japan's Daicel Corporation.

PHARMAJET firmographics

Firmographics
Name
PHARMAJET
Legal name
PharmaJet, Inc.
Website
https://pharmajet.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
PharmaJet is a Golden, Colorado-based commercial-stage MedTech company that develops WHO-prequalified, FDA-cleared, and CE-marked spring-powered needle-free jet injection systems (Tropis, Stratis) for vaccines and therapeutics, serving pharmaceutical/biotech partners and global immunization programs across 20+ million administered doses.
Ownership category
akta.pro rank

PHARMAJET industry classification

Industry
Product category
Needle-free injection medical devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Needle-free injection
  • Intradermal delivery systems
  • Vaccine delivery devices
  • Jet injection technology
  • Medical device manufacturing

Where PHARMAJET is headquartered

Location

Headquarters

HQ city
Golden
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PHARMAJET business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Hardware Sales: PharmaJet generates revenue through the sale of its needle-free injection systems (Tropis and Stratis devices) and associated sterile, auto-disabling syringes. The company sells directly to healthcare providers, pharmaceutical partners, and through distribution agreements with regional partners. Pricing is comparable to traditional needle injections with reduced dose volume enabling cost savings for intradermal delivery.
  2. Technology Licensing and Partnership Agreements: Revenue generated through strategic partnerships with pharmaceutical and biotechnology companies where PharmaJet's technology is used for partner product delivery. This includes co-development agreements, technology transfer arrangements, and potentially milestone payments tied to clinical and commercialization progress.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goComparable to needle and syringe pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

PHARMAJET product offering

Product offering

Core offering

PharmaJet develops and manufactures spring-powered needle-free jet injection systems for delivering vaccines and therapeutics without needles. Its two commercial systems are the Tropis ID device for 0.1 mL intradermal injections and the Stratis IM/SC device for 0.5 mL intramuscular and subcutaneous injections, both cleared by FDA, CE Marked, and WHO PQS prequalified, with reusable auto-disabling syringe components sold alongside the devices.

Product overview

PharmaJet offers a portfolio of commercial-stage needle-free injection systems consisting of two core products: the Tropis® ID system for 0.1 mL intradermal delivery and the Stratis® IM/SC system for 0.5 mL intramuscular and subcutaneous injections. Both systems are spring-powered devices that deliver medications through a narrow high-velocity fluid jet in approximately 0.1 seconds without needles. The company is also developing needle-free self-injection pens for home use targeting chronic disease management. All products share the core needle-free delivery technology platform, with variations in dose volume and injection depth to serve different therapeutic applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Tropis: Needle-free Injection System for 0.1 mL intradermal injections. WHO prequalified, CE marked device for precise intradermal delivery.
  • Stratis
  • Precision Delivery Systems

Products and services

  • Tropis ID Needle-free Injection System A spring-powered needle-free injection system that delivers a precise 0.1 mL intradermal dose in approximately 1/10 of a second, designed for intradermal vaccine and therapeutic delivery. WHO prequalified and CE Mark certified, used in polio immunization campaigns and clinical vaccine delivery globally.
  • Stratis IM/SC Needle-free Injection System A spring-powered needle-free injection system for 0.5 mL intramuscular and subcutaneous injections, used to deliver medications and vaccines. Has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification.
  • Needle-free Self-Injection Pens Proprietary reusable needle-free self-injector pens being developed for home use, designed to improve patient compliance and address needle aversion, particularly for chronic disease management and metabolic peptide therapies.

Quantifiable outcome

  • 87% of recipients report no pain with Tropis; 69% reduced soreness compared to needles
  • +8 more outcomes

Companies that use PHARMAJET

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

PHARMAJET technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

PHARMAJET partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and secondary.

  • African Field Epidemiology Network (AFENET)coreChannel Partner/ Reseller/ Distributor · 7 May 2026Partnership with AFENET to deploy Tropis ID needle-free injection system for delivering approximately 1.4 million doses of fractional inactivated polio vaccine (fIPV) during polio immunization campaigns in Nigeria. AFENET collaborates with ministries of health to implement polio eradication initiatives.
  • Brazilian Tuberculosis Research Network (REDE-TB)secondaryStrategic or Co-development Partner · 24 March 2026Clinical study agreement to evaluate Tropis ID needle-free injection device as delivery system for tuberculin skin test. Study will assess accuracy, workflow efficiency, safety, and acceptability compared to traditional needle and syringe administration.
  • EVA Pharma (ATR Affiliate)coreChannel Partner/ Reseller/ Distributor · 30 October 2025Distribution agreement signed at CPHI meeting in Frankfurt for Tropis needle-free injection systems covering Egypt and Middle East and Africa region. Collaboration aims to improve immunization coverage, reduce costs, and increase vaccine acceptance through Tropis distribution, technology transfer, and local manufacturing.
  • Immuno CuresecondaryStrategic or Co-development Partner · 19 June 2025Agreement for clinical development of HIV therapeutic DNA vaccine (ICVAX) delivered via PharmaJet Tropis needle-free injection system. Aims to evaluate safety and immunogenicity in human clinical study.
  • ScancellcoreStrategic or Co-development Partner · 9 January 2025Partnership for development and commercialization of SCIB1/iSCIB1+ DNA immunotherapy for advanced melanoma using PharmaJet Stratis needle-free delivery. Phase 2 clinical data showed positive results; advancing to late-stage clinical development.
  • Nykode TherapeuticscoreStrategic or Co-development PartnerPharmaJet delivery systems used in multiple Nykode clinical trials for cancer vaccines targeting cervical cancer, head and neck cancers, and metastatic solid tumors. Positive interim Phase 2 results announced for HPV+ cervical cancer trial.
  • Gennova BiopharmaceuticalscoreStrategic or Co-development PartnerGEMCOVAC-OM self-amplifying mRNA COVID-19 booster vaccine exclusively delivered with Tropis needle-free system. Received emergency use authorization in India - world's first room temperature stable mRNA vaccine.
  • Zydus LifesciencescoreStrategic or Co-development PartnerZyCoV-D plasmid DNA COVID-19 vaccine exclusively delivered with Tropis. World's first plasmid DNA COVID-19 vaccine for administration in humans, receiving emergency use authorization in India.
  • World Health Organization (WHO)coreStrategic or Co-development PartnerWHO supported development of Tropis system and awarded WHO PQS prequalification. Tropis selected for WHO polio eradication campaigns in Pakistan, Nigeria, Afghanistan, and Somalia.
  • PATHcoreStrategic or Co-development PartnerInternational health organization co-supported development of Tropis needle-free system. Partner on Nigeria implementation study for routine immunization using Tropis-delivered fIPV.
  • CDCsecondaryStrategic or Co-development PartnerU.S. Centers for Disease Control supported development of Tropis system. House-to-house campaign administration study published in MMWR.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

PHARMAJET competitors and assessment

Company assessment

Direct peers

  • Portal Instruments: Portal Instruments is developing a high-velocity jet injection platform for needle-free drug delivery, including biologic and large-volume applications. It is the most direct competitor to PharmaJet in needle-free jet injection technology, targeting pharmaceutical partners for drug-device combination products.
  • INJEX Pharma: INJEX Pharma offers a spring-powered needle-free jet injection system for insulin and other injectable therapies, marketed primarily in Europe and select international markets. It directly competes with PharmaJet's Tropis and Stratis devices in the needle-free injection device category.
  • Crossject: Crossject develops needle-free jet injection systems (Zeneo platform) for emergency and routine drug delivery, including vaccines and biologics. It competes with PharmaJet in the needle-free injection device category and has pursued similar partnerships with pharmaceutical companies and global health organizations.
  • Antares Pharma (Halozyme): Antares Pharma, acquired by Halozyme, developed auto-injector and needle-free jet injection platforms for self-administered pharmaceuticals. It is a direct peer in the drug delivery device space serving pharmaceutical partners, though with a stronger focus on auto-injectors than pure jet injection.
  • Bioject Medical Technologies: Bioject was a pioneer in needle-free jet injection technology, developing the Biojector 2000 and partnering with pharmaceutical companies for vaccine and therapeutic delivery. It is a historical direct competitor to PharmaJet in the jet injection space, though its commercial footprint has been limited.

Broad incumbents

  • BD (Becton Dickinson): BD is the dominant global manufacturer of conventional needle-and-syringe injection systems, prefilled syringes, and auto-injectors used across pharmaceutical and immunization applications. It is a broad incumbent that competes with PharmaJet in the underlying drug delivery device market, including immunization programs.
  • West Pharmaceutical Services: West Pharmaceutical Services is a leading provider of drug delivery device components and containment systems, including prefilled syringe and auto-injector platforms for pharmaceutical partners. It serves overlapping pharmaceutical customers as PharmaJet and is a broad incumbent in injectable drug delivery.
  • Stevanato Group: Stevanato Group provides drug containment, delivery devices, and integrated solutions for pharmaceutical and biotechnology partners, including self-injection platforms. It competes with PharmaJet's emerging self-injection pen initiative and serves similar pharmaceutical customers across biologics and vaccines.
  • Ypsomed: Ypsomed is a leading developer and manufacturer of self-injection pen platforms and auto-injectors for pharmaceutical and biotech partners, particularly in diabetes, obesity (GLP-1), and biologics. It is a direct competitor to PharmaJet's self-injection pen initiative for chronic disease and metabolic peptide markets.

Emerging players

  • Inovio Pharmaceuticals: Inovio develops DNA vaccines and CELLECTRA electroporation delivery technology for cancer and infectious disease applications. It competes with PharmaJet in the delivery technology for next-generation DNA/mRNA vaccines, though using electroporation rather than jet injection, and serves overlapping pharmaceutical and academic research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

PHARMAJET social profiles

Digital presence

PHARMAJET compliance and trust

Trust signal

Compliance4 records

PHARMAJET financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PHARMAJET leadership team

Management profile

Number of profiles

Profiles16 records

PHARMAJET funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PHARMAJET M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PHARMAJET

What does PHARMAJET do?

PharmaJet develops and manufactures spring-powered needle-free jet injection systems for delivering vaccines and therapeutics without needles. Its two commercial systems are the Tropis ID device for 0.1 mL intradermal injections and the Stratis IM/SC device for 0.5 mL intramuscular and subcutaneous injections, both cleared by FDA, CE Marked, and WHO PQS prequalified, with reusable auto-disabling syringe components sold alongside the devices.

Is PHARMAJET a public or private company?

PHARMAJET is a private company. It is classified as venture growth investor backed and is currently operating.

When was PHARMAJET founded?

PHARMAJET was founded in 2005. It employs 11 to 50 people.

Where is PHARMAJET based?

PHARMAJET is headquartered in Golden, United States, in the North America region.

How does PHARMAJET make money?

Two revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are technology Licensing and Partnership Agreements.

Who are PHARMAJET's main competitors?

Direct peers on record are Portal Instruments, INJEX Pharma, Crossject, Antares Pharma (Halozyme) and Bioject Medical Technologies. Broad incumbents are BD (Becton Dickinson), West Pharmaceutical Services, Stevanato Group and Ypsomed. Inovio Pharmaceuticals is listed as an emerging player.

Does PHARMAJET have an API?

No public API is recorded for PHARMAJET.

What industry is PHARMAJET in?

PHARMAJET's product category is Needle-free injection medical devices. Its primary akta.pro industry code is HLAHAIAD, Needle-Free Injection Systems (Jet Injectors/Microneedle Patches), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PagePharmaJet® Achieves Significant Milestone with 25M Intradermal Injections Delivered for Polio EradicationPharmaJet announced its Tropis needle-free injection system delivered over 25 million injections for polio eradication, supporting campaigns in Pakistan, Nigeria, Afghanistan, and Somalia. The system improved vaccine coverage by over 18%, reduced costs up to 47%, and achieved 97% healthcare worker preference. PharmaJet is expanding into additional countries and developing new applications.Business Wire BlogPharmaJet Highlights Vaccine Development Opportunities and Real-World Impact with Needle-Free Delivery at World Vaccine Congress EuropePharmaJet will present a panel at World Vaccine Congress Europe on October 19, 2026, on needle-free vaccine delivery. The company's Tropis system has administered over 20 million polio vaccine injections worldwide, and the panel will discuss adoption barriers and clinical benefits.FinancialContent Business PagePharmaJet Highlights Vaccine Development Opportunities and Real-World Impact with Needle-Free Delivery at World Vaccine Congress EuropePharmaJet will present a panel on needle-free vaccine delivery at World Vaccine Congress Europe on October 19, 2026, in Amsterdam. The company highlights its Tropis system, which has administered over 20 million polio vaccine injections worldwide, and discusses benefits for oncology and other indications.Business Wire BlogPublished Review Highlights Advantages of Needle-free Intradermal Delivery Over Traditional Needle and SyringeA review of 59 published manuscripts on needle-free intradermal delivery found that technologies like PharmaJet's Tropis offer advantages over traditional needles, including improved acceptability, coverage, and cost savings. Tropis is the only commercialized, WHO-prequalified ID technology in the review, with over 20 million syringes provided for campaigns.AETOSWirePharmaJet Announces Implementation Study Results: Increased Coverage, Cost Savings, and Preference for Routine Polio Immunization with Tropis® ID Needle-free DeliveryPharmaJet announced study results from Nigeria showing Tropis ID needle-free delivery increased IPV coverage by 11.2% and cut costs by up to 47%. Over 96% of caregivers would return for future vaccinations, and 95% of healthcare workers preferred Tropis. The company reaffirmed its commitment to the Global Polio Eradication Initiative.AETOSWirePharmaJet® Enters into MOU Agreement with Egyptian UPA and EVA Pharma to provide Needle-Free Delivery for Routine Immunization in EgyptPharmaJet signed an MOU with Egypt's UPA and EVA Pharma to integrate needle-free polio vaccine delivery into routine immunization. The agreement covers distribution, technology transfer, and manufacturing, with Tropis offering up to 38% cost savings over six years. The initiative aims to support Egypt's universal health insurance and pandemic preparedness.AETOSWirePharmaJet to Highlight Benefits of Needle-free Intradermal Delivery at Medical Conference in EthiopiaPharmaJet will present study results on needle-free intradermal vaccine delivery at a February 2025 conference in Addis Ababa. The presentation highlights Tropis, a WHO-prequalified device used for polio vaccinations in over 10 million children, and cites a Nigeria study showing improved coverage and acceptability.BioSpacePharmaJet® Tropis® Needle-free Injection System Selected to Deliver 1.4 Million Polio Vaccine Doses in NigeriaPharmaJet announced its Tropis needle-free injection system will deliver about 1.4 million polio vaccine doses in Nigeria, partnering with AFENET in Sokoto. Nigeria reported 66 polio cases in 2025, and Tropis has supplied over 20 million pediatric injections globally.Business Wire BlogPharmaJet® Tropis® Needle-free Injection System Selected to Deliver 1.4 Million Polio Vaccine Doses in NigeriaPharmaJet announced its Tropis needle-free injection system will deliver about 1.4 million polio vaccine doses in Nigeria, partnering with AFENET in Sokoto. A prior trial showed Tropis delivery increased second-dose coverage by 11.2% and cut costs by up to 47%. The company has supplied over 20 million Tropis injections globally.BioSpaceBrazilian Tuberculosis Research Network to Evaluate PharmaJet® Needle-free Tropis® ID Injection Device as Delivery System for Tuberculin Skin TestPharmaJet announced that its partner, the Brazilian Tuberculosis Research Network (REDE-TB), plans to initiate a clinical study evaluating the accuracy, workflow efficiency, safety, and acceptability of PharmaJet's Tropis ID Needle-free Injection System as a delivery system for tuberculin skin tests, compared to traditional needle and syringe administration. The study aims to address TB infection testing bottlenecks, which a recent Lancet publication identified as a key failure point in TB programs due to drop-out during and after testing. With more than 1.23 million people dying from tuberculosis globally in 2024, the evaluation seeks to determine if a less painful, less intimidating delivery method can improve test acceptance and program completion rates.